Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Takeda Pharmaceutical Ltd ADR (TAK)

Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 56,925,552
  • Shares Outstanding, K 3,181,976
  • Annual Sales, $ 30,238 M
  • Annual Income, $ 712,320 K
  • EBIT $ 2,182 M
  • EBITDA $ 11,532 M
  • 60-Month Beta 0.02
  • Price/Sales 1.88
  • Price/Cash Flow 5.60
  • Price/Book 1.14

Options Overview Details

View History
  • Implied Volatility 24.62% (-3.48%)
  • Historical Volatility 19.42%
  • IV Percentile 32%
  • IV Rank 13.12%
  • IV High 72.40% on 10/29/25
  • IV Low 17.40% on 03/24/25
  • Expected Move (DTE 12) 0.79 (4.42%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 26
  • Volume Avg (30-Day) 308
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 8,937
  • Open Int (30-Day) 10,344
  • Expected Range 17.10 to 18.68

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.21
  • Number of Estimates 1
  • High Estimate 0.21
  • Low Estimate 0.21
  • Prior Year 0.16
  • Growth Rate Est. (year over year) +31.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.78 +13.37%
on 01/21/26
17.99 -0.53%
on 02/06/26
+2.10 (+13.30%)
since 01/06/26
3-Month
13.56 +31.93%
on 11/10/25
17.99 -0.53%
on 02/06/26
+4.25 (+31.16%)
since 11/06/25
52-Week
12.99 +37.72%
on 10/30/25
17.99 -0.53%
on 02/06/26
+4.28 (+31.45%)
since 02/06/25

Most Recent Stories

More News
Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead

Year-to-Date Revenue Declined by 2.8% at Constant Exchange Rate (CER), 3.3% at Actual Exchange Rates (AER); ...

TAK : 17.89 (+0.51%)
Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1

− GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with Less Than or Equal to 2 µg/mL IgA in a 10% Solution is Now Available by Prescription for Intravenous or Subcutaneous...

TAK : 17.89 (+0.51%)
Stocks in play: Cineplex

Announced today that, starting January 20, its $5 Tuesdays return for a limited time, running through ...

CGX.TO : 9.74 (-0.92%)
TAK : 17.89 (+0.51%)
Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics

SAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced...

ONCY : 0.8859 (+5.89%)
CGON : 50.36 (+2.36%)
TAK : 17.89 (+0.51%)
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera ...

PTGX : 84.49 (+4.74%)
TAK : 17.89 (+0.51%)
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants...

TAK : 17.89 (+0.51%)
British Columbia reimburses FRUZAQLATM (fruquintinib capsules) for the treatment of metastatic colorectal cancer (mCRC)

TORONTO , Dec. 16, 2025 /CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce that FRUZAQLA TM (fruquintinib capsules) will now be reimbursed by BC Cancer as a treatment option for...

TAK : 17.89 (+0.51%)
Breakthrough ASH Data Drives Blood Cancer Market To $240B Valuation

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – The 2025 American Society of Hematology meeting showcased pivotal advances in blood cancer treatment, with...

PTGX : 84.49 (+4.74%)
KPTI : 6.26 (+2.79%)
GTBP : 0.5389 (+8.54%)
GSK : 60.23 (+1.79%)
TAK : 17.89 (+0.51%)
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety Signals ...

TAK : 17.89 (+0.51%)
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy

− Phase 1b, Open-Label Study Follow Up Shows Stable Kidney Function (eGFR) in Patients Treated with Investigational Mezagitamab Through Week 96 – 18 Months After Last Dose 1 ...

TAK : 17.89 (+0.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide...

See More

Key Turning Points

3rd Resistance Point 18.30
2nd Resistance Point 18.14
1st Resistance Point 18.02
Last Price 17.89
1st Support Level 17.73
2nd Support Level 17.57
3rd Support Level 17.45

See More

52-Week High 17.99
Last Price 17.89
Fibonacci 61.8% 16.08
Fibonacci 50% 15.49
Fibonacci 38.2% 14.90
52-Week Low 12.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar